OncoPro NCCN Lung Cancer Panel with PD-L1 Test
Comprehensive Lung Cancer Genetic Analysis
The OncoPro NCCN Lung Cancer Panel with PD-L1 Test represents a cutting-edge approach to personalized cancer care. This comprehensive molecular diagnostic test utilizes advanced Next Generation Sequencing technology to analyze multiple genetic biomarkers simultaneously from a simple blood sample. By examining both genetic mutations and immune checkpoint markers, this test provides oncologists with critical information needed to develop targeted treatment strategies for lung cancer patients.
What This Test Measures and Detects
Our advanced panel evaluates 11 crucial biomarkers that play significant roles in lung cancer progression and treatment response:
- EGFR mutations – Critical for determining eligibility for EGFR tyrosine kinase inhibitors
- ALK rearrangements – Essential for ALK inhibitor therapy selection
- ERBB2 (HER2) alterations – Important for targeted therapy options
- BRAF mutations – Key for BRAF inhibitor treatments
- MET amplifications – Relevant for MET-targeted therapies
- RET fusions – Crucial for RET inhibitor eligibility
- ROS1 rearrangements – Important for ROS1-targeted treatments
- NTRK1 fusions – Essential for TRK inhibitor therapy
- KRAS mutations – Significant for treatment pathway decisions
- Microsatellite Instability (MSI) – Determines immunotherapy responsiveness
- PD-L1 expression – Critical for immune checkpoint inhibitor therapy
Who Should Consider This Test
This comprehensive lung cancer panel is recommended for patients experiencing:
- Newly diagnosed non-small cell lung cancer (NSCLC)
- Recurrent or metastatic lung cancer
- Progressive disease despite standard treatments
- Need for targeted therapy selection
- Consideration for immunotherapy options
- Family history of lung cancer or genetic predisposition
- Unexplained respiratory symptoms with suspicious imaging findings
Benefits of Taking the OncoPro NCCN Lung Cancer Panel
Choosing this comprehensive genetic testing approach offers numerous advantages:
- Personalized Treatment Planning – Identifies specific genetic alterations to match with targeted therapies
- Immunotherapy Guidance – PD-L1 expression analysis helps determine immune checkpoint inhibitor suitability
- Comprehensive Biomarker Analysis – Single test evaluates multiple critical biomarkers simultaneously
- Minimally Invasive Sampling – Uses liquid biopsy technology from blood samples
- Evidence-Based Recommendations – Follows NCCN guidelines for lung cancer biomarker testing
- Treatment Optimization – Helps avoid ineffective treatments and potential side effects
- Clinical Trial Eligibility – Identifies patients who may qualify for novel targeted therapy trials
Understanding Your Test Results
Your test results will provide detailed information about the genetic landscape of your lung cancer. Positive findings for specific mutations may indicate eligibility for targeted therapies, while PD-L1 expression levels guide immunotherapy decisions. Our comprehensive report includes:
- Detailed mutation analysis for all 10 genetic biomarkers
- PD-L1 expression scoring and interpretation
- Microsatellite instability status
- Clinical significance of each finding
- Potential targeted therapy options
- Immunotherapy suitability assessment
- NCCN guideline-based treatment recommendations
Your oncologist will review these results with you to develop a personalized treatment plan tailored to your specific genetic profile.
Test Pricing and Details
| Test Component | Price (USD) |
|---|---|
| Discount Price | $3510 |
| Regular Price | $3900 |
| Turnaround Time | 35 Working Days |
| Sample Type | 20 mL whole blood in 2 Streck tubes OR 8 mL whole blood in 1 Lavender Top (EDTA) tube |
Nationwide Accessibility
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our network ensures that advanced genetic testing is accessible to patients nationwide.
Book Your Test Today
Take the first step toward personalized lung cancer treatment. Our experienced team is ready to assist you with scheduling and answer any questions about the OncoPro NCCN Lung Cancer Panel with PD-L1 Test.
Call or WhatsApp: +1(267) 388-9828
Schedule your comprehensive genetic analysis and receive the detailed insights needed to guide your lung cancer treatment journey. Our dedicated specialists will help you understand the testing process and ensure you receive the highest quality care.
